Evidence map›Paper›PMID 40883295›Full record

ArticleCell death discovery2025

Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway.

So Young Kim, Bin Lee, Je-Jung Lee, Man Sup Kwak, Woo Joong Rhee, In Ho Park, Jeon-Soo Shin

Abstract read
In one paragraph

Article in Cell death discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

So Young KimDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0003-1166-9853
Bin LeeDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
Je-Jung LeeDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
Man Sup KwakDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.
Woo Joong RheeDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0001-9690-0553
In Ho ParkInstitute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, South Korea.ORCID http://orcid.org/0000-0003-2190-5469
Jeon-Soo ShinDepartment of Microbiology, Yonsei University College of Medicine, Seoul, South Korea. jsshin6203@yuhs.ac.ORCID http://orcid.org/0000-0002-8294-3234

Funding

National Research Foundation of Korea (NRF) RS-2019-NR040072National Research Foundation of Korea (NRF) RS-2022-NR068972
6 · The paper itself

Abstract

The lymphotoxin β receptor (LTβR), a key activator of non-canonical NF-κB signaling, is expressed in various cells, including cancer cells. Although high expression of LTβR has been associated with poor patient prognosis and drug resistance, conflicting evidence suggested that LTβR induces apoptosis. To investigate the functional role of LTβR in tumors, we performed LTβR knockdown in cancer cells. We found that LTβR knockdown induced senescence phenomena such as reduced cell number; increased cell size; increased SA-β-Gal activity; and upregulated p53, MDM2 and p21 expression. Moreover, LTβR knockdown induced p21-mediated senescence in p53 WT cancer cells, but not in p53 mutant cancer cells. The level of p53 is regulated by MDM2 and MDMX; MDMX enhances MDM2 activity but is also subject to MDM2-mediated degradation in the nucleus. We found that the intracellular domain of LTβR bound to MDMX thereby inhibited its nuclear translocation, which in turn reduced MDMX ubiquitination and consequently promoted p53 ubiquitination. Additionally, tumors derived from B16F10

Identifiers

PMID40883295
PMCPMC12397326

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.